Oncolytics reports faster enrollment in REO 033 colorectal cancer study
Nearly all Part A sites are active, an interim update is expected by year-end 2026, and the FDA has aligned on a possible accelerated approval route.
SEC filing (2)
Latest
3 stories
Yesterday
Sagimet Biosciences prices $107.5 million stock offering
The company plans to use proceeds to fund a Phase 3 acne trial for denifanstat and advance other pipeline programs.
SEC filing
Tuesday, August 11
Sagimet updates Q2 2026 results with new investor presentation filing
The company reiterated its $257.6 million cash position and confirmed plans for a Phase 3 acne trial of denifanstat in the second half of 2026, alongside a new investor slide deck.
SEC filing